Paloma Partners’s scPharmaceuticals SCPH Stock Holding History

Paloma Partners’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-30,000	Closed	-$96K	–	2253
2019 Q2	$96K	Buy	+30,000	New	+$98.1K	﹤0.01%	1633

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

AIM

Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's SCPH Position: Q3 2019 in Review

Paloma Partners sold out of scPharmaceuticals (SCPH) in Q3 2019, closing a stake of 30,000 shares — an estimated $96K sold.

Paloma Partners first reported a position in SCPH in Q2 2019 and held it in 1 quarter. The position peaked at $96K in Q2 2019. 26 funds tracked by Wall St. Rank hold SCPH as of Q3 2019.

Paloma Partners reported no remaining scPharmaceuticals position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 30,000 scPharmaceuticals shares in Q3 2019, an estimated $96K.
Paloma Partners first reported a position in scPharmaceuticals in Q2 2019 and held it in 1 quarter.
Paloma Partners's scPharmaceuticals position peaked at $96K in Q2 2019.
26 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.